A Clinico-biological Database of Lung Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-13

Study Completion Date

2032-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective, single-center, interventional study is conducted in order to achieve a biological bank accompanied by clinical data. Blood samples, optional tumor tissue and fecal samples are collected, processed and banked for all the included subjects. Those samples are collected before the start of treatment, at the time of first tumor assessment, at the time of first and second disease progression. The subjects are treated according to standard of care.

Clinical data are collected at each sampling time. The primary objective of the study is to identify biological, clinical and tumoral factors associated with tumor response according SOC treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of Clinical and Biological Database on Bronchial Cancer

NCT07085429

Lung Cancer Bronchial Cancer

NOT_YET_RECRUITING NA

Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.

NCT02785562

Lung Cancer

COMPLETED NA

Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer

NCT04589013

Non-small Cell Lung Cancer

COMPLETED

Breath Analysis to Diagnose Lung Cancer

NCT03250390

Lung Cancer

COMPLETED NA

Clinico-biological Data Collection Study of Metastatic Lung Cancer

NCT04944030

Lung Cancer

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tissue biopsies

additional biopsies will be performed during a diagnostic or therapeutic procedure, in order to sample tumor tissue and healthy tissue.

Intervention Type PROCEDURE

blood sampling

additional blood samples will be collected during a SOC sampling procedure (2 EDTA 7.5 ml tubes, 2 SST 7.5 ml tubes and 2 citrate 5 ml tubes)

Intervention Type PROCEDURE

DNA banking

constitutional and somatic genetic alterations will be analysed for subjects who consent, from either tumor or healthy tissue, or whole blood buffy coat after centrifugation

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented new diagnosis of lung cancer by histology or cytology, or lung tumor leading to lung cancer suspicion without diagnosis for which an antineoplastic treatment is indicated
* Indication of a treatment by surgery, chemotherapy, radio-chemotherapy, radiotherapy or targeted therapy as first line of lung cancer treatment
* ability of the subject to follow study procedures
* Age \> 18 years
* Subject must have at least one measurable and/or assessable lesion in regard with RECIST 1.1 criteria
* Subject is registered with a social security scheme
* Subject is taken in charge at Pneumology department of Lille UH
* Subject has signed an informed consent form

Exclusion Criteria

* Patient with a history of treatment by antineoplastic chemotherapy, radio-chemotherapy, radiotherapy or targeted therapy, or presenting a contra indication to antineoplastic treatment administration
* Subject is not willing to sign the informed consent form
* Subject is not registered with a social security scheme
* Subject is not francophone
* Subject is deprived of his/her liberty or under trusteeship

Eligible Sex

ALL

Accepts Healthy Volunteers

No